Tr1X Revenue and Competitors
Estimated Revenue & Valuation
- Tr1X's estimated annual revenue is currently $5.3M per year.
- Tr1X's estimated revenue per employee is $155,000
Employee Data
- Tr1X has 34 Employees.
- Tr1X grew their employee count by 42% last year.
Tr1X's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head Regulatory Affairs | Reveal Email/Phone |
3 | Director, Process Development | Reveal Email/Phone |
4 | Senior Principal Scientist | Reveal Email/Phone |
5 | Process Engineer II - Tr1X Bio | Reveal Email/Phone |
6 | Senior Research Associate | Reveal Email/Phone |
7 | Senior Research Associate | Reveal Email/Phone |
8 | Senior Scientist | Reveal Email/Phone |
9 | Senior Scientist, Bioanalytical Sciences | Reveal Email/Phone |
Tr1X Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Tr1X?
Tr1X Inc. (pr. \Trix\) is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of first-in-class cell therapy products aimed at rebalancing the immune system and restoring homeostasis, leading to long term tolerance. Tr1X is headquartered in La Jolla, CA.
keywords:N/AN/A
Total Funding
34
Number of Employees
$5.3M
Revenue (est)
42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.5M | 34 | 6% | N/A |
#2 | $5.7M | 34 | -8% | N/A |
#3 | $3.9M | 34 | N/A | N/A |
#4 | $2.6M | 34 | 31% | $43M |
#5 | $3.6M | 34 | -41% | $132.5M |